Advertisement
News
Advertisement

Miraculins Granted U.S. Patent on PreVu(R) Skin Cholesterol Technology

Mon, 06/11/2012 - 3:45am
The Associated Press

(http://www.miraculins.com/ )

Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company

focused on developing and commercializing diagnostic tests and risk

assessment technologies for unmet clinical needs, announces today that

it has received a Notice of Allowance from the United States Patent

and Trademark Office for a patent that covers use of

spectrophotometric measurements for the non-invasive analysis of skin

cholesterol. The allowed patent will cover elements that are key to

the PreVu@ Non-Invasive Skin Cholesterol Point of Care (POC) Test,

specifically relating to the PreVu Handheld Spectrophotometer, which

is used to read the level of skin cholesterol during the test.

"We are pleased with the allowance of this patent which significantly

strengthens Miraculins' intellectual property portfolio in the U.S.

market. In addition to broadening coverage of the PreVu technology,

which is protected by a number of patents and patents pending in North

America and internationally, this is another important step towards

introducing the PreVu technology into one of the largest markets in

the world," stated Christopher J. Moreau, President and Chief

Executive Officer of Miraculins Inc.

In the U.S., the FDA has directed that "Skin cholesterol as measured

by the PreVu POC can be used as part of risk assessment for coronary

heart disease in persons with a history of myocardial infarction

and/or in persons suspected of having significant multi-vessel

coronary artery disease (greater than 50% stenosis in greater than 1

vessel as diagnosed by coronary angiography) where further diagnostic

evaluation is being considered. Test results, when considered in

conjunction with clinical evaluation, blood cholesterol tests and

other risk factors identified for coronary artery disease, will aid

the physician in focusing diagnostic and patient management options."

Miraculins recently announced the launch of a new English Canadian

website for PreVu (www.prevu.com(http://www.prevu.com)). In addition,

the Company has established distribution partnerships for the Canadian

medical community and Canadian retail pharmacy market with The Stevens

Company and with Pear Healthcare Solutions Inc., respectively.

About The PreVu@ Non-Invasive Skin Cholesterol Test

Skin cholesterol is the cholesterol that has been deposited and

diffused into tissue, as opposed to freely circulating in the

bloodstream, and has been shown in clinical trials to be strongly

associated with significant CAD as measured by treadmill stress

testing, coronary angiography, coronary calcium, carotid artery

thickening and carotid artery plaque. The PreVu POC Test is completely

painless, non-invasive, involves no blood draw or needles, requires no

overnight fasting and involves no handling of potentially hazardous

biomaterials. It has been developed to provide new and additive

information about CAD risk that is independent of traditional risk

factors, such as blood cholesterol, to help physicians more

effectively assess their patients' risk. The test is conducted on the

palm of the hand in less than 5 minutes with results being immediately

available.

About Miraculins Inc.

Miraculins is a medical diagnostic development company focused on

acquiring, developing and commercializing non-invasive tests for unmet

clinical needs. A significant number of promising diagnostic

opportunities remain un-commercialized because of the sizable gap

between the discovery stage, when research institutions are typically

involved, and the commercialization stage, when the larger commercial

enterprises become interested. Miraculins has direct experience in

bridging this gap. The Company's PreVu technology is a revolutionary

new coronary artery disease risk assessment technology that measures

cholesterol levels in a patient's skin non-invasively, painlessly and

without the need for fasting. Miraculins is also advancing a suite of

biomarkers to aid in the early detection of the devastating disease of

pregnancy known as preeclampsia. The Company's preeclampsia program is

partnered with Alere, Inc. (NYSE: ALR) (formerly known as Inverness

Medical Innovations), one of the world's largest diagnostic companies.

For more information on Miraculins please visit

www.miraculins.com(http://www.miraculins.com).

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute

forward-looking information within the meaning of applicable Canadian

provincial securities legislation (collectively, "forward-looking

statements"). These forward-looking statements relate to, among other

things, our objectives, goals, targets, strategies, intentions, plans,

beliefs, estimates and outlook, including, without limitation, our

anticipated future operating results, and can, in some cases, be

identified by the use of words such as "believe," "anticipate,"

"expect," "intend," "plan," "will," "may" and other similar

expressions. In addition, any statements that refer to expectations,

projections or other characterizations of future events or

circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on

information currently available to management. Certain material

factors or assumptions are applied in making forward-looking

statements, and actual results may differ materially from those

expressed or implied in such statements. Important factors that could

cause actual results to differ materially from these expectations

include, among other things: Miraculins' early stage of development,

lack of product revenues and history of operating losses,

uncertainties related to clinical trials and product development,

rapid technological change, uncertainties related to forecasts,

competition, potential product liability, additional financing

requirements and access to capital, unproven markets, supply of raw

materials, income tax matters, management of growth, partnerships for

development and commercialization of technology, effects of insurers'

willingness to pay for products, system failures, dependence on key

personnel, foreign currency risk, risks related to regulatory matters

and risks related to intellectual property and other risks detailed

from time to time in Miraculins' filings with Canadian securities

regulatory authorities, as well as Miraculins' ability to anticipate

and manage the risks associated with the foregoing. Additional

information about these factors and about the material factors or

assumptions underlying such forward-looking statements may be found in

the body of this news release. Miraculins cautions that the foregoing

list of important factors that may affect future results is not

exhaustive. When relying on Miraculins' forward-looking statements to

make decisions with respect to Miraculins investors and others should

carefully consider the foregoing factors and other uncertainties and

potential events.

These risks and uncertainties should be considered carefully and

prospective investors should not place undue reliance on the

forward-looking statements. Although the forward-looking statements

contained in this press release are based upon what management

believes to be reasonable assumptions, Miraculins cannot provide

assurance that actual results will be consistent with these

forward-looking statements. Miraculins undertakes no obligation to

update or revise any forward-looking statement.

PreVu@ is a registered trademark of Miraculins Inc. All Rights

Reserved. 2012.

Neither TSX Venture Exchange nor its Regulation Services Provider (as

that term is defined in the policies of the TSX Venture Exchange)

accepts responsibility for the adequacy or accuracy of this release.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading